Delivery Order SPE2DB22D2211-SPE2DB25FRXCL

Award Date 5/13/25
Potential Completion Date 5/14/25
Potential Value $8.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $2,895.45 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of RABAVERT rabies vaccine with diluents. This award falls under a larger indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to provide pharmaceutical products and medical supplies to DLA Troop...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract valued at $8,945.46 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of RABAVERT RABIES VACC W-DILUENTS and has an ultimate completion date of May 10, 2024. This order is placed under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, worth up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary...
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corporation, a major pharmaceutical distributor, a $13,241.60 firm-fixed-price delivery order contract for RABAVERT rabies vaccine with diluents. This contract has a period of performance through July 25, 2024 and is not set aside for any specific business type. Amerisourcebergen, through its Corporate Office division, is a significant supplier of pharmaceutical products and medical supplies to various federal agencies and...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order worth $1,497.82 to Amerisourcebergen Drug Corp, a wholly-owned subsidiary of Amerisourcebergen Corporation, for the supply of RABAVERT rabies vaccine with diluents. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary contract vehicle for the company to deliver pharmaceutical...
The Defense Logistics Agency (DLA) Troop Support Medical has awarded a $2,895.45 firm fixed price delivery order to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, to provide RABAVERT rabies vaccine with diluents. The order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the company to deliver pharmaceuticals and medical supplies...
The U.S. Defense Logistics Agency (DLA) awarded a $19,970.00 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RABAVERT rabies vaccine with diluents. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,161.90 firm fixed-price delivery order is for the procurement of RABAVERT rabies vaccine with diluents, with a performance period through March 6, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RABAVERT rabies vaccine with diluents. The contract has a total ceiling value of $17,123.97 and a performance period through May 2, 2025. It is a firm fixed-price, non-set-aside contract. AmerisourceBergen holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which serves...
This is a delivery order worth $8,509.86 awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, Corporate Office Division, a major pharmaceutical distributor in the United States. The contract is for the supply of RABAVERT RABIES VACC W-DILUENTS, a critical medical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for a...
The Defense Logistics Agency (DLA) awarded a $1,544.24 firm fixed price delivery order to Amerisourcebergen Drug Corp, a for-profit subsidiary of Amerisourcebergen Corporation, to provide RABAVERT RABIES VACCINE WITH DILUENTS. The delivery order has a completion date of February 2, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB25FRXCL
    Delivery Order

The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order worth $8,803.37 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for the supply of RABAVERT RABIES VACC W-DILUENTS, a rabies vaccine, with a performance period through May 14, 2025. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through December 2026. The contract is not set-aside and allows for multiple delivery orders across different therapeutic categories, positioning AmerisourceBergen as a critical vendor in supporting federal medical procurement needs, particularly for military and veteran healthcare systems.

Generated 8/12/25, 11:49 AM